Canadian Hallucinogen Producer Optimi Health (OPTH.US) IPO Priced at $6-8 per Share, Plans to Raise $15 Million

LootboxPhobia · 2026-03-16T08:16:55+00:00

Optimi Health is a Canadian-based pharmaceutical company focused on MDMA and psilocybin. The company plans to issue 2.1 million shares through an IPO priced between $6 and $8 per share, raising $15 million. Founded in 2020, Optimi has obtained multiple pharmaceutical production licenses and plans to list on NASDAQ under the ticker symbol OPTH.

LootboxPhobia

2026-03-16 08:16:55

Abstract generation in progress

The Smart Finance APP has learned that Optimi Health (OPTH.US), a Canadian-based pharmaceutical company focused on MDMA and psilocybin, announced its IPO terms last Friday. The company, located in Princeton, Canada, plans to issue 2.1 million shares at an offering price range of $6 to $8 per share, aiming to raise $15 million.

The company is a licensed pharmaceutical manufacturer in Canada, producing controlled substances such as MDMA and psilocybin. It operates two production facilities in British Columbia and holds multiple licenses to produce, import, and distribute these substances within legal limits. Its approved operations cover the entire process from extracting active ingredients from plants to processing and supplying hallucinogens in regulated quantities.

Founded in 2020, Optimi Health plans to list on the Nasdaq under the ticker symbol OPTH. The exclusive bookrunner for this IPO is Joseph Gunnar.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.